Skip to Content
 
Jennifer A.  Pietenpol

Jennifer A. Pietenpol, Ph.D.

Director, Vanderbilt-Ingram Cancer Center
Executive Vice President for Research, VUMC
Benjamin F. Byrd, Jr. Professor of Oncology
Professor of Biochemistry, Cancer Biology and Otolaryngology

Contact Information:

Vanderbilt University Medical Center
652 Preston Research Building
Nashville, TN 37232-0146
615-936-1512

Profile

Jennifer A. Pietenpol, Ph.D., is the Director of the Vanderbilt-Ingram Cancer Center, the Benjamin F. Byrd, Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology. Pietenpol’s research focuses on breast cancer and the p53 family signaling network—the most frequently targeted network for mutation in human tumors.
Read more...

Jennifer A. Pietenpol, Ph.D., is the Director of the Vanderbilt-Ingram Cancer Center, the Benjamin F. Byrd, Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology. Pietenpol’s research focuses on breast cancer and the p53 family signaling network—the most frequently targeted network for mutation in human tumors. Recently, Pietenpol has integrated her research expertise in tumor suppressor genes and molecular genetics with bioinformatic analysis of high dimensional genomic data sets to molecularly subtype difficult-to-treat, triple negative breast cancer. Her results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy. Her research has impacted many areas of science and medicine and she has translated her discoveries into clinical impact for breast cancer patients. Pietenpol’s research is funded by the National Cancer Institute, the Susan G. Komen for the Cure Foundation, and the Department of Defense Breast Cancer Program.

In 2008, the President appointed Pietenpol to a six-year term on the National Cancer Advisory Board. Also, Dr. Pietenpol serves on the external advisory boards for eight NCI Comprehensive Cancer Centers and leads two as Chair. In 2011, Pietenpol was appointed as member of the Susan G. Komen for the Cure Foundation Scientific Advisory Committee and as a member of the Frederick National Laboratory for Cancer Research Advisory Committee. Recently, Dr. Pietenpol completed a three-year, elected term on the AACR Board of Directors. This year she will begin a three-year term as a Member of the Institute of Medicine, National Cancer Policy Forum.

In 1997, Pietenpol received the Burroughs Wellcome New Investigator Award in Toxicology; in 2004, she was honored with the Excellence in Teaching Award at Vanderbilt for her mentoring of graduate and medical students. She was inducted into the Johns Hopkins Society of Scholars (2009) and received the Carleton College Distinguished Alumni Achievement Award in 2011. In 2012, she was elected as a fellow of the American Association for the Advancement of Science for outstanding contributions to the field of cancer research, particularly the involvement of signaling networks in breast and other cancers.

After graduating from Carleton with honors in biology and as a member of Sigma Xi, Pietenpol earned a Ph.D. in cell biology at Vanderbilt University School of Medicine in 1990. She continued her postgraduate training at Johns Hopkins Oncology Center (now Sidney Kimmel Comprehensive Cancer Center) before returning to Vanderbilt in 1995 as an assistant professor of biochemistry. She achieved the rank of full professor in 2002. Pietenpol has served as associate editor or on the editorial board for numerous biomedical research journals. She has authored or co-authored over 120 articles published in the peer-reviewed scientific literature.

Education
  • Ph.D., Vanderbilt University, Nashville, Tennessee (1990)
  • B.A., Carleton College, Northfield, Minnesota (1986) 
Postdoctoral Training
  • Fellowship, Johns Hopkins University (1994) 
Research Description

Some defining properties of tumor cells are increased cell proliferation, decreased cell death and genomic instability. These characteristics are acquired as a consequence of mutations in genes that control the fidelity and frequency of cell division as well as the ability of the cell to initiate pathways of apoptosis. A goal of the ongoing cancer-based research in the Pietenpol Laboratory is to provide new therapeutic approaches that specifically target the molecular interactions and biochemical pathways that are changed in tumor cells. The Laboratory was one of the first to pioneer chromatin immunoprecipatation techniques allowing analysis of p53 and identification of target genes involved in tumor suppression. They discovered that p63 signaling confers key epithelial properties to cells by regulating novel target genes and transcriptional programs controling mesenchymal phenotypes. Subsequently, the Pietenpol group began mechanistic studies on p73, deciphered the functional p73 binding sites in the genome, discovered numerous p73-target mRNAs and microRNAs, and was the first to link the mTOR signaling pathway to regulation of p73 activity. Importantly, the research defined a mTOR-p73 signaling pathway involved in mesenchymal differentiation and a resulting p73 gene signature that classifies rhabdomyosarcomas by subtype and patient outcome. Most recently, Pietenpol and her team have integrated research expertise in tumor suppressor genes and molecular genetics with bioinformatic analysis of high dimensional genomic data sets to molecularly subtype difficult-to-treat, triple negative breast cancer. The results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy. The overall goals of her research are to use bench-based discoveries to advance patient care.

Publications
  • Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast [print-electronic]. 2015 Nov; 24 Suppl 2: S36-40. PMID: 26253813, PMCID: PMC4641762, PII: S0960-9776(15)00147-2, DOI: 10.1016/j.breast.2015.07.009, ISSN: 1532-3080.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26253813.
  • Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25972361.
  • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer [print-electronic]. 2015 Jan 1/1/2015; 121(1): 8-16. PMID: 25043972, PMCID: PMC4270831, DOI: 10.1002/cncr.28914, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25043972.
  • Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015; e31-9. PMID: 25993190, PII: 00115000e31, DOI: 10.14694/EdBook_AM.2015.35.e31, ISSN: 1548-8756.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993190.
  • Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS ONE. 2015; 10(5): e0125482. PMID: 25965342, PMCID: PMC4428765, PII: PONE-D-14-51553, DOI: 10.1371/journal.pone.0125482, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25965342.
  • Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res [print-electronic]. 2014 Jun 6/1/2014; 74(11): 3180-94. PMID: 24662921, PMCID: PMC4096808, PII: 0008-5472.CAN-13-3415, DOI: 10.1158/0008-5472.CAN-13-3415, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24662921.
  • Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin. Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24536073.
  • Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24356096.
  • Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J. Pathol. 2014 Jan; 232(2): 142-50. PMID: 24114677, PMCID: PMC4090031, DOI: 10.1002/path.4280, ISSN: 1096-9896.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24114677.
  • Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y. Detection of internal exon deletion with exon Del. BMC Bioinformatics. 2014; 15: 332. PMID: 25322818, PMCID: PMC4288651, PII: 1471-2105-15-332, DOI: 10.1186/1471-2105-15-332, ISSN: 1471-2105.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25322818.
  • Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 2013 Dec 12/15/2013; 19(24): 6696-702. PMID: 24345920, PMCID: PMC3880773, PII: 19/24/6696, DOI: 10.1158/1078-0432.CCR-13-1746, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24345920.
  • Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res [print-electronic]. 2013 Oct 10/1/2013; 19(19): 5533-40. PMID: 23948975, PMCID: PMC3813597, PII: 1078-0432.CCR-13-0799, DOI: 10.1158/1078-0432.CCR-13-0799, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23948975.
  • Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J. Clin. Oncol [print-electronic]. 2012 Oct 10/10/2012; 30(29): 3648-50. PMID: 22965952, PII: JCO.2012.44.0412, DOI: 10.1200/JCO.2012.44.0412, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22965952.
  • Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform [print-electronic]. 2012; 11: 147-56. PMID: 22872785, PMCID: PMC3412597, PII: cin-11-2012-147, DOI: 10.4137/CIN.S9983, ISSN: 1176-9351.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22872785.
  • Ye F, Bauer JA, Pietenpol JA, Shyr Y. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. BMC Genomics [print-electronic]. 2012; 13 Suppl 8: S3. PMID: 23281588, PMCID: PMC3535706, PII: 1471-2164-13-S8-S3, DOI: 10.1186/1471-2164-13-S8-S3, ISSN: 1471-2164.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23281588.
  • Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011 Jul; 121(7): 2750-67. PMID: 21633166, PMCID: PMC3127435, PII: 45014, DOI: 10.1172/JCI45014, ISSN: 1558-8238.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21633166.
  • Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2011 Feb 2/1/2011; 108(5): 2076-81. PMID: 21245298, PMCID: PMC3033306, PII: 1011936108, DOI: 10.1073/pnas.1011936108, ISSN: 1091-6490.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21245298.
  • Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res [print-electronic]. 2010 Jan 1/15/2010; 16(2): 681-90. PMID: 20068102, PMCID: PMC2892225, PII: 1078-0432.CCR-09-1091, DOI: 10.1158/1078-0432.CCR-09-1091, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20068102.
  • Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr Y, Boukamp P, Pietenpol JA. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Dis. 2010; 1: e74. PMID: 21151771, PMCID: PMC3000738, DOI: 10.1038/cddis.2010.49, ISSN: 2041-4889.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21151771.
  • Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res [print-electronic]. 2010; 12(3): R41. PMID: 20576088, PMCID: PMC2917036, PII: bcr2595, DOI: 10.1186/bcr2595, ISSN: 1465-542X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20576088.
  • Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA. ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy. Mol. Cancer. 2010; 9: 95. PMID: 20429933, PMCID: PMC2873442, PII: 1476-4598-9-95, DOI: 10.1186/1476-4598-9-95, ISSN: 1476-4598.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20429933.
  • Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle [print-electronic]. 2009 Nov 11/15/2009; 8(22): 3702-6. PMID: 19855172, PII: 10036, ISSN: 1551-4005.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19855172.
  • Barton CE, Tahinci E, Barbieri CE, Johnson KN, Hanson AJ, Jernigan KK, Chen TW, Lee E, Pietenpol JA. DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Dev. Biol [print-electronic]. 2009 May 5/1/2009; 329(1): 130-9. PMID: 19272371, PMCID: PMC2690611, PII: S0012-1606(09)00166-3, DOI: 10.1016/j.ydbio.2009.02.036, ISSN: 1095-564X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19272371.
  • Rosenbluth JM, Pietenpol JA. MTOR regulates autophagy-associated genes downstream of p73. Autophagy [print-electronic]. 2009 Jan; 5(1): 114-6. PMID: 19001857, PMCID: PMC2792737, PII: 7294, ISSN: 1554-8635.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19001857.
  • Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes Dev. 2008 Oct 10/1/2008; 22(19): 2591-5. PMID: 18832062, PII: 22/19/2591, DOI: 10.1101/gad.1727408, ISSN: 0890-9369.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18832062.
  • Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol. Cell. Biol [print-electronic]. 2008 Oct; 28(19): 5951-64. PMID: 18678646, PMCID: PMC2547001, PII: MCB.00305-08, DOI: 10.1128/MCB.00305-08, ISSN: 1098-5549.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18678646.
  • Perez CA, Ott J, Mays DJ, Pietenpol JA. P63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene [print-electronic]. 2007 Nov 11/15/2007; 26(52): 7363-70. PMID: 17563751, PII: 1210561, DOI: 10.1038/sj.onc.1210561, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17563751.
  • Schavolt KL, Pietenpol JA. P53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. Oncogene [print-electronic]. 2007 Sep 9/13/2007; 26(42): 6125-32. PMID: 17404570, PII: 1210441, DOI: 10.1038/sj.onc.1210441, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17404570.
  • Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007 May 5/1/2007; 101(1): 9-33. PMID: 17340614, DOI: 10.1002/jcb.21255, ISSN: 0730-2312.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17340614.
  • Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther. 2007 Apr; 6(4): 561-70. PMID: 17495520, PMCID: PMC3395216, PII: 3851, ISSN: 1538-4047.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17495520.
  • Perez CA, Pietenpol JA. Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle [print-electronic]. 2007 Feb 2/1/2007; 6(3): 246-54. PMID: 17297308, PII: 3801, ISSN: 1551-4005.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17297308.
  • Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006 Aug 8/1/2006; 66(15): 7589-97. PMID: 16885358, PII: 66/15/7589, DOI: 10.1158/0008-5472.CAN-06-2020, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16885358.
  • Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E. The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophys. J [print-electronic]. 2006 Jul 7/1/2006; 91(1): 330-42. PMID: 16603489, PMCID: PMC1479054, PII: S0006-3495(06)71732-5, DOI: 10.1529/biophysj.105.078303, ISSN: 0006-3495.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16603489.
  • Barbieri CE, Pietenpol JA. P63 and epithelial biology. Exp. Cell Res [print-electronic]. 2006 Apr 4/1/2006; 312(6): 695-706. PMID: 16406339, PII: S0014-4827(05)00557-4, DOI: 10.1016/j.yexcr.2005.11.028, ISSN: 0014-4827.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16406339.
  • Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 2006 Mar 3/1/2006; 12(5): 1570-6. PMID: 16533783, PII: 12/5/1570, DOI: 10.1158/1078-0432.CCR-05-2304, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16533783.
  • Hearnes JM, Mays DJ, Schavolt KL, Tang L, Jiang X, Pietenpol JA. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell. Biol. 2005 Nov; 25(22): 10148-58. PMID: 16260627, PMCID: PMC1280257, PII: 25/22/10148, DOI: 10.1128/MCB.25.22.10148-10158.2005, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16260627.
  • Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle [print-electronic]. 2005 May; 4(5): 710-6. PMID: 15846104, PII: 1685, ISSN: 1551-4005.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15846104.
  • Barbieri CE, Pietenpol JA. P53 family members: similar biochemistry, different biology. Cancer Biol. Ther [print-electronic]. 2005 Apr; 4(4): 419-20. PMID: 15908776, PII: 1760, ISSN: 1538-4047.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15908776.
  • Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res. 2005 Mar 3/15/2005; 65(6): 2314-20. PMID: 15781645, PII: 65/6/2314, DOI: 10.1158/0008-5472.CAN-04-3449, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15781645.
  • Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope. 2004 Dec; 114(12): 2063-72. PMID: 15564824, PII: 00005537-200412000-00001, DOI: 10.1097/01.mlg.0000149437.35855.4b, ISSN: 0023-852X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15564824.
  • Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S. Head and neck cancer: meeting summary and research opportunities. Cancer Res. 2004 Nov 11/1/2004; 64(21): 8126-9. PMID: 15520225, PII: 64/21/8126, DOI: 10.1158/0008-5472.CAN-04-2445, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15520225.
  • Westfall MD, Pietenpol JA. P63: Molecular complexity in development and cancer. Carcinogenesis [print-electronic]. 2004 Jun; 25(6): 857-64. PMID: 15033906, PII: bgh148, DOI: 10.1093/carcin/bgh148, ISSN: 0143-3334.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15033906.
  • Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res [print-electronic]. 2004; 6(3): R215-31. PMID: 15084245, PMCID: PMC400675, PII: bcr778, DOI: 10.1186/bcr778, ISSN: 1465-542X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15084245.
  • Barbieri CE, Barton CE, Pietenpol JA. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J. Biol. Chem [print-electronic]. 2003 Dec 12/19/2003; 278(51): 51408-14. PMID: 14555649, PII: M309943200, DOI: 10.1074/jbc.M309943200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14555649.
  • Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003 Nov 11/1/2003; 63(21): 7113-21. PMID: 14612504, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14612504.
  • Chakravarthy B, Pietenpol JA. Combined modality management of breast cancer: development of predictive markers through proteomics. Semin. Oncol. 2003 Aug; 30(4 Suppl 9): 23-36. PMID: 12908134, PII: S0093775403002677, ISSN: 0093-7754.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12908134.
  • Jo D, Lin Q, Nashabi A, Mays DJ, Unutmaz D, Pietenpol JA, Ruley HE. Cell cycle-dependent transduction of cell-permeant Cre recombinase proteins. J. Cell. Biochem. 2003 Jul 7/1/2003; 89(4): 674-87. PMID: 12858334, DOI: 10.1002/jcb.10542, ISSN: 0730-2312.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12858334.
  • Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope. 2003 Jun; 113(6): 936-9. PMID: 12782800, DOI: 10.1097/00005537-200306000-00004, ISSN: 0023-852X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12782800.
  • Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol. 2003 Apr; 23(7): 2264-76. PMID: 12640112, PMCID: PMC150720, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12640112.
  • Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem [print-electronic]. 2003 Mar 3/21/2003; 278(12): 10368-73. PMID: 12529318, PII: M211981200, DOI: 10.1074/jbc.M211981200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12529318.
  • Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 2003 Mar; 24(3): 139-45. PMID: 12628359, PII: S0165-6147(03)00026-9, DOI: 10.1016/S0165-6147(03)00026-9, ISSN: 0165-6147.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12628359.
  • Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 2002 Dec 12/27/2002; 181-182: 475-81. PMID: 12505356, PII: S0300483X02004602, ISSN: 0300-483X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12505356.
  • Sniezek JC, Matheny KE, Burkey BB, Netterville JL, Pietenpol JA. Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg. 2002 Jun; 126(6): 598-601. PMID: 12087324, PII: S0194599802000244, ISSN: 0194-5998.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12087324.
  • Eichten A, Westfall M, Pietenpol JA, Münger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology. 2002 Mar 3/30/2002; 295(1): 74-85. PMID: 12033767, PII: S0042682202913759, DOI: 10.1006/viro.2002.1375, ISSN: 0042-6822.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12033767.
  • Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Arch. Otolaryngol. Head Neck Surg. 2002 Feb; 128(2): 167-76. PMID: 11843726, PII: ooa00268, ISSN: 0886-4470.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11843726.
  • Pawlak MR, Banik-Maiti S, Pietenpol JA, Ruley HE. Protein arginine methyltransferase I: substrate specificity and role in hnRNP assembly. J. Cell. Biochem. 2002; 87(4): 394-407. PMID: 12397599, DOI: 10.1002/jcb.10307, ISSN: 0730-2312.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12397599.
  • Ji C, Amarnath V, Pietenpol JA, Marnett LJ. 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem. Res. Toxicol. 2001 Aug; 14(8): 1090-6. PMID: 11511183, PII: tx000186f, ISSN: 0893-228X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11511183.
  • Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 2001 Jul 7/15/2001; 61(14): 5480-5. PMID: 11454695, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11454695.
  • Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 2001 May; 21(10): 3375-86. PMID: 11313463, PMCID: PMC100259, DOI: 10.1128/MCB.21.10.3375-3386.2001, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11313463.
  • Stewart ZA, Pietenpol JA. P53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol. 2001 Mar; 14(3): 243-63. PMID: 11258974, ISSN: 0893-228X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11258974.
  • Stewart ZA, Tang LJ, Pietenpol JA. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene. 2001 Jan 1/4/2001; 20(1): 113-24. PMID: 11244509, PII: 1204060, DOI: 10.1038/sj.onc.1204060, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11244509.
  • Stewart ZA, Pietenpol JA. Syk: a new player in the field of breast cancer. Breast Cancer Res [print-electronic]. 2001; 3(1): 5-7. PMID: 11250739, PMCID: PMC138668, ISSN: 1465-5411.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11250739.
  • Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein LA, Yu J, Kinzler KW, Vogelstein B, Hill DE, Pietenpol JA. P53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 2000 Aug 8/1/2000; 156(1): 63-72. PMID: 10840161, PII: S0304-3835(00)00441-9, ISSN: 0304-3835.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10840161.
  • Flatt PM, Pietenpol JA. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab. Rev. 2000 Aug; 32(3-4): 283-305. PMID: 11139130, DOI: 10.1081/DMR-100102335, ISSN: 0360-2532.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11139130.
  • Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. P53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 2000 Jun; 20(12): 4210-23. PMID: 10825186, PMCID: PMC85790, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10825186.
  • Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia. 2000 May; 2(3): 261-72. PMID: 10935512, PMCID: PMC1507570, ISSN: 1522-8002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10935512.
  • Peek RM, Blaser MJ, Mays DJ, Forsyth MH, Cover TL, Song SY, Krishna U, Pietenpol JA. Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res. 1999 Dec 12/15/1999; 59(24): 6124-31. PMID: 10626802, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10626802.
  • Stewart ZA, Pietenpol JA. Cell cycle checkpoints as therapeutic targets. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4): 389-400. PMID: 10705922, ISSN: 1083-3021.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10705922.
  • Stewart ZA, Mays D, Pietenpol JA. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 1999 Aug 8/1/1999; 59(15): 3831-7. PMID: 10447002, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10447002.
  • Szak ST, Pietenpol JA. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J. Biol. Chem. 1999 Feb 2/5/1999; 274(6): 3904-9. PMID: 9920946, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9920946.
  • Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 1999 Jan; 5(1): 35-42. PMID: 9918200, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9918200.
  • Stewart ZA, Leach SD, Pietenpol JA. P21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 1999 Jan; 19(1): 205-15. PMID: 9858545, PMCID: PMC83879, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9858545.
  • Szak, S.T. and Pietenpol, J.A. High affinity insertion/deletion lesion binding by p53: Evidence for a role of the p53 central domain. J. Biol. Chem. 1999; 274: 3904-9.
  • Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 1998 Nov 11/13/1998; 273(46): 30777-84. PMID: 9804855, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9804855.
  • Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, Pietenpol JA. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res. 1998 Aug 8/1/1998; 58(15): 3231-6. PMID: 9699647, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9699647.
  • Flatt PM, Price JO, Shaw A, Pietenpol JA. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth Differ. 1998 Jul; 9(7): 535-43. PMID: 9690621, ISSN: 1044-9523.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9690621.
  • Ji C, Rouzer CA, Marnett LJ, Pietenpol JA. Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis. 1998 Jul; 19(7): 1275-83. PMID: 9683189, ISSN: 0143-3334.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9683189.
  • Jennings MT, Pietenpol JA. The role of transforming growth factor beta in glioma progression. J. Neurooncol. 1998 Jan; 36(2): 123-40. PMID: 9525812, ISSN: 0167-594X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9525812.
  • Flatt, P.M., Price, J.O., and Pietenpol, J.A. Cell cycle response to DNA damage differs in normal human keratinocytes and fibroblasts. Cell Growth Diff. 1998; 9: 535-43.
  • Ji C, Marnett LJ, Pietenpol JA. Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. Oncogene. 1997 Nov 11/27/1997; 15(22): 2749-53. PMID: 9401002, DOI: 10.1038/sj.onc.1201441, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9401002.
  • Koury MJ, Horne DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN, Hard R, Koury ST. Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Blood. 1997 Jun 6/15/1997; 89(12): 4617-23. PMID: 9192787, ISSN: 0006-4971.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9192787.
  • Pietenpol JA. A commentary on the 1996 American Association for Cancer Research Meeting--Cancer susceptibility genes and molecular carcinogenesis. Biochim. Biophys. Acta. 1996 Aug 8/8/1996; 1288(1): R5-8. PMID: 8764846, ISSN: 0006-3002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8764846.
  • Pietenpol JA, Lengauer C, Jordan J, Kinzler KW, Vogelstein B. Mammalian cells resistant to tumor suppressor genes. Proc. Natl. Acad. Sci. U.S.A. 1996 Aug 8/6/1996; 93(16): 8390-4. PMID: 8710881, PMCID: PMC38681, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8710881.
  • Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995 Mar 3/15/1995; 55(6): 1206-10. PMID: 7882309, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/7882309.
  • Sato, Y., Suto, Y., Pietenpol, J.A., Golub, T.R. Gilliland, G., Davis, E., Le Beau, M.M., Vogelstein, B., Rowley, J., Bohlander, S.K. TEL and KIPI define the smallest region of deletions on 12pl3 in hematopoietic malignancies. Blood. 1995; 86: 1525-33.
  • Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res. 1994 Jul 7/15/1994; 54(14): 3714-7. PMID: 8033089, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8033089.
  • Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. U.S.A. 1994 Mar 3/15/1994; 91(6): 1998-2002. PMID: 8134338, PMCID: PMC43296, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8134338.
  • el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 3/1/1994; 54(5): 1169-74. PMID: 8118801, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8118801.
  • Pietenpol, J.A., Papadopoulos, N., Markowitz, S., Willson, J.K.V., Kinzler, KW., and Vogelstein, B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res. 1994; 54: 3714-7.
  • Pietenpol JA, Vogelstein B. Tumour suppressor genes. No room at the p53 inn. Nature. 1993 Sep 9/2/1993; 365(6441) Sect. 17,8.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8361531.
  • Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 4/29/1993; 362(6423): 857-60. PMID: 8479525, DOI: 10.1038/362857a0, ISSN: 0028-0836.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8479525.
  • Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 1993 Mar; 4(3): 193-201. PMID: 8466857, ISSN: 1044-9523.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8466857.
  • Dagnino L, Pietenpol JA, Yang EY, Moses HL. Transforming growth factor regulation of keratinocyte growth. Recent Results Cancer Res. 1993; 128: 15-29. PMID: 8356316, ISSN: 0080-0015.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8356316.
  • Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992 May 5/8/1992; 256(5058): 827-30. PMID: 1589764, ISSN: 0036-8075.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1589764.
  • Münger K, Pietenpol JA, Pittelkow MR, Holt JT, Moses HL. Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ. 1992 May; 3(5): 291-8. PMID: 1633111, ISSN: 1044-9523.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1633111.
  • El-Delry, W.S., Kem, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. Definition of consensus binding site for p53. Nat. Genet. 1992; 1: 45-9.
  • Pietenpol JA, Münger K, Howley PM, Stein RW, Moses HL. Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc. Natl. Acad. Sci. U.S.A. 1991 Nov 11/15/1991; 88(22): 10227-31. PMID: 1946442, PMCID: PMC52901, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1946442.
  • Münger K, Yee CL, Phelps WC, Pietenpol JA, Moses HL, Howley PM. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 1991 Jul; 65(7): 3943-8. PMID: 1645802, PMCID: PMC241434, ISSN: 0022-538X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1645802.
  • Moses HL, Pietenpol JA, Münger K, Murphy CS, Yang EY. TGF beta regulation of epithelial cell proliferation: role of tumor suppressor genes. Int. Symp. Princess Takamatsu Cancer Res. Fund. 1991; 22: 183-95. PMID: 1844240.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1844240.
  • Moses HL, Yang EY, Pietenpol JA. Regulation of epithelial proliferation by TGF-beta. Ciba Found. Symp. 1991; 157: 66-74; discussion 75. PMID: 2070684, ISSN: 0300-5208.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2070684.
  • Munger, K., Yee, C.L., Phelps, W.C., Pietenpol, J.A., Moses, H.L., and Howley, P.M. Biochemical and biological differences between E7 oncoproteins of the high- and low- risk human papillomavirus types are determined by amino-terminal sequences. J. of Virol. 1991; 65: 3943-8.
  • Murphy CS, Pietenpol JA, Münger K, Howley PM, Moses HL. C-myc and pRB: role in TGF-beta 1 inhibition of keratinocyte proliferation. Cold Spring Harb. Symp. Quant. Biol. 1991; 56: 129-35. PMID: 1819482, ISSN: 0091-7451.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1819482.
  • Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990 Oct 10/19/1990; 63(2): 245-7. PMID: 2208284, PII: 0092-8674(90)90155-8, ISSN: 0092-8674.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2208284.
  • Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow MR, Münger K, Howley PM, Moses HL. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell. 1990 Jun 6/1/1990; 61(5): 777-85. PMID: 2140528, PII: 0092-8674(90)90188-K, ISSN: 0092-8674.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2140528.
  • Pietenpol JA, Holt JT, Stein RW, Moses HL. Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc. Natl. Acad. Sci. U.S.A. 1990 May; 87(10): 3758-62. PMID: 2187192, PMCID: PMC53982, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2187192.
  • Pietenpol JA, Howe PH, Cunningham MR, Leof EB. Interferon alpha/beta modulation of growth-factor-stimulated mitogenicity in AKR-2B fibroblasts. J. Cell. Physiol. 1989 Dec; 141(3): 453-60. PMID: 2687295, DOI: 10.1002/jcp.1041410302, ISSN: 0021-9541.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2687295.